Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
about
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.Innate and Adaptive Immune Response in Fabry DiseaseQuality of life in patients with Fabry disease: a systematic review of the literature.Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.Myocardial lipid content in Fabry disease: a combined 1H-MR spectroscopy and MR imaging study at 3 Tesla.The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsEnzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease.Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.Genetic Screening of Mutations Associated with Fabry Disease in a Nationwide Cohort of Juvenile Idiopathic Arthritis Patients.Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.Progress in the treatment of small fiber peripheral neuropathy.Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.Advances in renal genetic diagnosis.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.High variability of Fabry disease manifestations in an extended Italian family.Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations.Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group.Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.Precision medicine for cardiovascular disease : Learning lessons from cardiomyopathies.Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
P2860
Q31060724-5681E864-C906-4C9E-9BC4-7D3C1C241A4FQ33645550-3449F92E-D1CE-47F4-A693-498660F05CECQ33886219-88314FEB-ECDE-4DC6-8655-E6B6309844EEQ35247511-98537C2B-592A-421E-8A27-C64709F7B9E8Q35550696-E8DCA7FE-6FAB-4E6F-857F-06D215DA3F7BQ35800976-32EA7F91-CC0D-4512-916A-ACB995775725Q35849151-BC6DFAA6-CC25-4D3F-8DD8-21480BE6C67FQ36105190-80922D41-9091-409F-935A-C5910A1C39DAQ36177437-08CAB56D-8E12-444B-B2F2-66DB2F53CD30Q36213022-58925DF6-445D-4EA6-9E4B-DAECC8840B0CQ36309032-11190118-DC48-4A62-BB9B-42A7B3245A0AQ37284141-4570EEB8-85BD-44FB-AAFB-61F0C80C2EB1Q37591813-027FECFF-E585-433D-826D-2DF2829269E9Q37672375-0E1F6051-0DA6-4503-8997-AD0C9A041A87Q38230252-6775EB47-59DA-4D71-93A4-04850633F54BQ38349089-01B558CD-5FF8-46E0-8EC2-70BAE0EAC62BQ38672018-8D54F0EC-E4F4-4090-96C2-A6BCADF76895Q38673027-03CEB2F9-7CD5-4BB0-A5E9-2AC3FDCC3D5CQ38844401-9FF61C03-FD0E-4084-819A-76B3FEFBAF8BQ40155905-4F704E1C-921A-47DD-9D76-FF16F174E2ADQ41671504-4AD8E838-39D7-4F92-B039-FE56F2EE2473Q42374740-5C814829-B7DA-422E-8CFA-BCA0303B7CF8Q46881710-F46C68E2-2F34-46B2-A04F-FFC89499C35EQ48091189-CD25F341-345C-408F-9BFD-81360187DBBDQ50424267-889B8431-AA2F-418D-9955-4F80288BDD26Q50793921-87241C15-C03C-4ABA-9658-D2F758AE231DQ54945677-0FEF1A94-A68D-402A-B82A-A4ED4F28832EQ57291693-6B6B5299-4693-4C4D-A7C9-C4468519CD89
P2860
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Natural course of Fabry diseas ...... T in different disease stages.
@en
type
label
Natural course of Fabry diseas ...... T in different disease stages.
@en
prefLabel
Natural course of Fabry diseas ...... T in different disease stages.
@en
P2093
P2860
P1476
Natural course of Fabry diseas ...... T in different disease stages.
@en
P2093
Bouwien E Smid
Carla E M Hollak
Gabor E Linthorst
Marcel G W Dijkgraaf
Saskia M Rombach
P2860
P2888
P304
P356
10.1007/S10545-014-9677-8
P577
2014-02-04T00:00:00Z
P5875
P6179
1043451108